Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort
MetadataShow full item record
Breast cancerInflammationBiomarkersMenopausal statusAnthropometry
Cairat, M... [et al.]. Circulating inflammatory biomarkers, adipokines and breast cancer risk—a case-control study nested within the EPIC cohort. BMC Med 20, 118 (2022). [https://doi.org/10.1186/s12916-022-02319-y]
SponsorshipInstitut National du Cancer (INCA) France 2016-128; World Cancer Research Fund International (WCRF) 2017/1614; Ligue nationale contre le cancer; World Health Organization; NIHR Imperial Biomedical Research Centre (BRC); Danish Cancer Society; Ligue nationale contre le cancer; Institut Gustave Roussy; Mutuelle Generale de l'Education Nationale; Institut National de la Sante et de la Recherche Medicale (Inserm); Deutsche Krebshilfe; Helmholtz Association; Federal Ministry of Education & Research (BMBF); Fondazione AIRC per la ricerca sul cancro; Consiglio Nazionale delle Ricerche (CNR); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds; Dutch Prevention Funds; Netherlands Organization for Scientific Research (NWO); World Cancer Research Fund (WCRF), Statistics Netherlands; Health Research Fund (FIS) -Instituto de Salud Carlos III (ISCIII); Catalan Institute of Oncology -ICO (Spain); Swedish Cancer Society; Swedish Research Council; European Commission; County Councils of Skane; Vasterbotten (Sweden); Cancer Research UK 14136 C8221/A29017; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); European Commission 1000143 MR/M012190/1
Background: Inflammation has been hypothesized to play a role in the development and progression of breast cancer and might differently impact breast cancer risk among pre and postmenopausal women. We performed a nested case-control study to examine whether pre-diagnostic circulating concentrations of adiponectin, leptin, c-reactive protein (CRP), tumour necrosis factor-α, interferon-γ and 6 interleukins were associated with breast cancer risk, overall and by menopausal status. Methods: Pre-diagnostic levels of inflammatory biomarkers were measured in plasma from 1558 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. We used conditional logistic regression to estimate the odds ratios (ORs) of breast cancer at blood collection, per one standard deviation increase in biomarker concentration. Results: Cases were diagnosed at a mean age of 61.4 years on average 8.6 years after blood collection. No statistically significant association was observed between inflammatory markers and breast cancer risk overall. In premenopausal women, borderline significant inverse associations were observed for leptin, leptin-to-adiponectin ratio and CRP [OR= 0.89 (0.77–1.03), OR= 0.88 (0.76–1.01) and OR= 0.87 (0.75–1.01), respectively] while positive associations were observed among postmenopausal women [OR= 1.16 (1.05–1.29), OR= 1.11 (1.01–1.23), OR= 1.10 (0.99–1.22), respectively]. Adjustment for BMI strengthened the estimates in premenopausal women [leptin: OR = 0.83 (0.68– 1.00), leptin-to-adiponectin ratio: OR = 0.80 (0.66–0.97), CRP: OR = 0.85 (0.72–1.00)] but attenuated the estimates in postmenopausal women [leptin: OR = 1.09 (0.96–1.24), leptin-to-adiponectin ratio: OR = 1.02 (0.89–1.16), CRP: OR = 1.04 (0.92–1.16)]. Conclusions: Associations between CRP, leptin and leptin-to-adiponectin ratio with breast cancer risk may represent the dual effect of obesity by menopausal status although this deserves further investigation.